about
Molecular mechanisms of ATP secretion during immunogenic cell deathHomeostatic defects in interleukin 18-deficient mice contribute to protection against the lethal effects of endotoxin.Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.Trial watch: Prognostic and predictive value of the immune infiltrate in cancerAnticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effectsImprovement of immunogenic chemotherapy by STAT3 inhibition.The oncolytic peptide LTX-315 triggers immunogenic cell death.Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1.Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy.Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy.Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8.Chemotherapy and radiotherapy: cryptic anticancer vaccines.Desirable cell death during anticancer chemotherapy.The dendritic cell-tumor cross-talk in cancer.Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy.How to improve the immunogenicity of chemotherapy and radiotherapy.Autophagy and cellular immune responses.Autophagy-dependent ATP release from dying cells via lysosomal exocytosis.Therapy-induced microenvironmental changes in cancer.Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells.CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy.Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells.Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy.Cardiac glycosides exert anticancer effects by inducing immunogenic cell death.Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands.The renaissance of anti-neoplastic immunity from tumor cell demise.The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies.Phagocytosis of Candida albicans Inhibits Autophagic Flux in Macrophages.Crizotinib-induced immunogenic cell death in non-small cell lung cancerAuthor Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancerEndogenous and exogenous glucocorticoids abolish the efficacy of immune-dependent cancer therapiesStress-glucocorticoid-TSC22D3 axis compromises therapy-induced antitumor immunityMyeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity
P50
Q30408773-53CA47A1-9C81-4E13-8E2E-C60BEC07DEB0Q33802028-E7EC77F3-A79A-46C8-B6A5-2126FBF5A490Q34681370-DEE6C15A-49C7-4A24-A695-7D5339CDE777Q36456483-77A8CC1C-0A00-4646-998D-E51BE370443AQ36476123-14C680DC-A105-4F92-AD48-BF291CA2026CQ36710966-DDA75436-0895-4E2B-9816-E2C0750B2507Q36774984-60E2DA13-E19A-4DC6-B87D-CFC72D5AA1FAQ37012744-9B508875-1002-4171-B3A6-4037FDDD888FQ37028031-81FF631E-300E-458E-A891-1FC9CAD099F0Q37078968-0286E599-28D7-4C56-80FD-981AC2B9A49EQ37379408-85EC0C73-89AE-47B4-9F9B-AE4793451136Q37733918-36962798-8A2E-4725-9AEA-820EE867176DQ37801399-42E70BBF-DF91-44D7-B705-4E136983BC09Q37802625-995BA2D0-54E2-41B6-A786-74F99D0FCA4AQ37811696-DAE4EC99-E529-40D4-83D4-E848A970B3EDQ37836489-2C27C201-1961-4A30-86A1-2D5E46F2ECEDQ38131217-6FFE966B-38C5-4A08-8D82-C52B37E07DFEQ38132631-63D41CF3-ECEC-4A97-8758-525325103C90Q38756772-2273E4E4-2B65-4B2C-8CD4-CFF6AD51DE92Q38823705-F3345E3F-A8E3-4180-9AFD-C77AC12A7E39Q38849545-3332D25A-3EB1-49CF-AE6A-930461B60DA3Q39049614-D064C3A0-21C2-4B51-915A-F4086E1A1E27Q39170477-0CD86F01-9610-449E-AA0B-714F461BBCD6Q39173712-255A8288-5743-4D96-B774-672C514D06F2Q39311553-AB1C33A0-5314-4DB9-8584-BEDE6A5CB21CQ39752777-B6CAA66A-012E-443C-9BAE-5A9DCDEC00FAQ48193643-78992857-48CE-4DB1-BA4C-DCBF48095B52Q52641905-8E5AC668-62E3-43A9-9E1D-675955D43304Q55086718-345A01AF-2613-40C2-9A07-985457396EB8Q64086405-8BCED1FD-C5FA-4DFD-8E9D-82718FB1AB1EQ64106070-D9D11198-FD26-408F-AC40-EB9C847EB980Q89457533-11500ADA-F23F-403F-B248-58FB1567AA46Q90003912-890CF740-F4E2-423F-A558-282D23B52322Q94521960-9CE087B5-8385-424A-A3A3-FCC3AF28AF6C
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Yuting Ma
@ast
Yuting Ma
@en
Yuting Ma
@es
Yuting Ma
@sl
type
label
Yuting Ma
@ast
Yuting Ma
@en
Yuting Ma
@es
Yuting Ma
@sl
prefLabel
Yuting Ma
@ast
Yuting Ma
@en
Yuting Ma
@es
Yuting Ma
@sl
P106
P2038
P21
P31
P496
0000-0001-6267-1852